Amar capsule for pancreatitis treatment claim and it's scientific research or publication
Reading File
Searching the Web
Amar capsule pancreatitis treatment Ayurvedic herbal
Searching PubMed
Amar capsule pancreatitis herbal
Reading Web Page
https://padaav.com/wp-content/uploads/2022/03/Indigenous-Tre…
Searching PubMed
Ayurvedic herbo-mineral pancreatitis treatment
Reading Article
PMID: 37664250
Searching PubMed
Balendu Prakash pancreatitis Ayurvedic
Now I have enough information to give a thorough, well-researched answer.
Amar Capsule for Pancreatitis: Claims and Scientific Evidence
What is Amar?
Amar is a herbo-mineral formulation (HMF) rooted in Rasa Shastra, an ancient branch of Ayurveda that uses processed heavy metals as therapeutic agents. It was originally formulated by Late Vaidya Chandra Prakash of Meerut in the 1970s and was later revived and clinically documented by his son, Vaidya Balendu Prakash.
Composition:
- Mercury (Parad)
- Copper (Tamra)
- Sulphur (Gandhak)
- Luffa echinata Roxb. (Devdali - a bitter gourd relative)
- Clitoria ternatea L. (Aparajita - butterfly pea)
- Lemon juice
The raw metals undergo approximately 3 years of continuous Rasa Shastra processing (Shodhana/Marana) to convert them from toxic free metals into what practitioners describe as "medicinal mineral form." A patent application (PCT Application No. 3373/DEL/2014) was filed with the Indian Patent Office, Delhi in November 2014.
Dosage: 4 mg/kg body weight/day, divided into 3 doses, given with meals.
Treatment Claims
Amar is claimed to treat primarily Recurrent Acute/Chronic Pancreatitis (RACP) and related pancreatic conditions. Specific claims include:
- Anti-inflammatory action - reduction of pancreatic inflammation across all forms (acute, chronic, autoimmune, hereditary, groove, etc.)
- CA19-9 lowering - normalization of this pancreatic cancer biomarker (from levels of 38 to 4000 units) - claimed relevant since pancreatitis is a precursor for pancreatic cancer
- Structural improvement - reduction in pancreatic duct dilation (e.g., from 8 mm to 2.8 mm in one published case)
- Reduction in acute exacerbations - fewer hospitalizations in RACP patients
- Pancreatic cancer protection - implied by CA19-9 lowering, though not formally proven
Scientific Research and Publications
Animal/Preclinical Studies
- Two experimental studies in male albino Wistar rats using L-Arginine-induced chronic pancreatitis were conducted to evaluate Amar's protective properties. Both showed that Amar had "significantly strong pancreatitis protective properties" compared to Methylprednisolone (a corticosteroid). These were conducted at Vipragen Biosciences Limited, Mysuru.
- Toxicology studies (acute, sub-acute, and chronic) on rats showed the formulation is reportedly "completely safe for human consumption" at doses more than 3x the therapeutic dose.
- Characterization studies using XRD, EDAX, and SEM (non-destructive methods) were conducted under the guidance of Prof. S. Vasudevan, Department of Inorganic and Physical Chemistry, Indian Institute of Sciences (IISc), Bengaluru, confirming no traces of free metal in the finished product.
Clinical Publications
| Publication | Type | Key Finding |
|---|---|---|
| Prakash VB et al., Pancreat Disord Ther 2018 (doi:10.4172/2165-7092.1000196) | Observational study | Evaluation of Ayurvedic treatment protocol in 319 cases of different variants of pancreatitis |
| Prakash VB et al., Cureus 2023 (PMID 37664250) | Case Report | 14-year-old with hereditary pancreatitis - ATP led to disease arrestation, pancreatic duct diameter reduced from 8 mm to 2.8 mm after ~1 year |
The booklet "Indigenous Treatment of Pancreatitis" (available on padaav.com) compiles the clinical practice data, safety studies, and animal experiment results related to Amar.
Critical Assessment of the Evidence
Significant limitations must be acknowledged:
- No randomized controlled trials (RCTs) exist for Amar in pancreatitis. The highest level of evidence available is an observational case series and a single case report.
- All research originates from the same group (the Prakash family / PADAAV clinic), creating a significant conflict of interest with no independent replication.
- Mercury and Copper toxicity concerns - While Rasa Shastra processing is claimed to detoxify the metals, the mainstream medical and toxicology communities remain skeptical. Rasa Shastra preparations with heavy metals have been associated with heavy metal poisoning in published literature.
- No peer-reviewed publication in a high-impact indexed journal has validated these findings.
- The 2023 Cureus case report (the only indexed PubMed-searchable publication) is an Evidence Tier 8 (lowest) - a single case report. The authors themselves acknowledge: "further research and clinical studies are needed to validate the long-term benefits."
- The 2018 observational study was published in a low-impact open access journal.
Summary
Amar capsule has theoretical pharmacological rationale (herbal anti-inflammatory constituents in Luffa echinata and Clitoria ternatea), preclinical animal data, patient-reported outcomes, and one indexed case report supporting its use in pancreatitis. However, no high-quality RCT or independent validation exists. The heavy metal content (mercury, copper) raises legitimate safety concerns until more rigorous evidence is produced. It remains an investigational Ayurvedic formulation and cannot yet be considered a standard-of-care treatment by conventional evidence-based medicine standards.
Bottom line: Amar is a real, patented Ayurvedic herbo-mineral formulation with some preliminary animal and observational clinical data - but the scientific evidence is at a very early, low-quality stage. Patients should not substitute it for evidence-based pancreatitis management without specialist consultation.
This is a shared conversation. Sign in to Orris to start your own chat.